Serologicals Corp

Serologicals — Investor Presentation (January 2006)

28 slides from Serologicals's investor presentation, Jan 10, 2006

  1. Slide 1: 2006 Guidance

    Serologicals: Corporation 2006 Guidance building value, enhancing lives January 2006

  2. Slide 2: Safe Harbor Statement

    Serologicals Safe Harbor Chen: This presentation may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding industry trends, the Company's growth prospects and product development plans

  3. Slide 3: Pro Forma Disclosure Comment

    Serologicals Pro Forma Disclosure Comment Corporation This presentation will include discussion of “non-GAAP financial measures” as that term is defined in Regulation G. For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial meas

  4. Slide 4: Today's Overriding Message

    Serologicals Today’s Overriding Message Coes” * Serologicals is a high-growth company that consistently outperforms its peers and markets ¢ Our strategy: - Focus on select, high-growth markets where Serologicals can achieve and strengthen its leadership position - Sustain leadership in product devel

  5. Slide 5: Our Business Model

    Our Business Model 2. Develop “best in class” products / tools / services — internal = acquisitions = licensing / collaborations 1. pe ae 3. Leverage infrastructure select markets — sales force — research — R&D — bioprocessing — facilities 4. Kecu HGR growth, high margins, high shareowner value

  6. Slide 6: Serologicals in Action - A New Company

    Serologicals Serologicals in Action - ANew Company “ertion Last 5 years Number of acquisitions <>» Amount invested in >$400M acquisitions & infrastructure “ R&D staff additions ——€ 150+ >) Commercial staff additions F 165 (includes customer service & technical support) x4 if FA By

  7. Slide 7: The Foundation for Continued Success

    The Foundation for Continued Success Serologicals Corporation 60% Research e Broad portfolio and customer base e ~ 11,000 products © Proprietary * 70% revenues © Leadership in: ~ Kinases - Neuroscience - Stem cell research - Nuclear function ~ Antibodies ¢ Pioneer of kinase selectivity screening ser

  8. Slide 8: Extraordinary Financial Performance

    Extraordinary Financial Performance Revenues ($M) $54 U 03 + Midpoint of guidance range 04 0s Guidancett) Pro forma EPS Continuing Operations ($) z 94 $0.79 $0.71 $0.38 $033 Tt 04 catsarcat

  9. Slide 9: Impressive Organic Growth

    Serologicals Impressive Organic Growth Corporation Strong and Sustainable Organic Growth of 15% () Key Drivers of Organic Growth e Highest new product development and commercialization productivity in the industry e Sustaining leadership Kinase profiling and assays Nuclear function Stem cells Drug d

  10. Slide 10: 2005 in Review

    Serologicals 2005 in Review

  11. Slide 11: 2005 Guidance Reaffirmed

    2005 Guidance Reaffirmed Revised 2005 Guidance 13% ‘organic growth Revenue $265.0 - $270.0M G Bea “) wi G growth Pro forma EPS $0.92 - $0.95 . Gp We Plan to Meet or Exceed 2005 Guidance

  12. Slide 12: Key Accomplishments in 2005

    Serologicals Key Accomplishments in 2005 oa ¢ Introduced innovative products and broadened product portfolio - Expanded kinase assays and panel offerings - Introduced Onco-CYTE™ to the EX-CYTE® franchise - Acquired UCOE gene expression technology ¢ Increased value of new products released through ki

  13. Slide 13: The Results in 2005 - Superior Growth

    Serologicals The Results in 2005 - Superior Growth —“*reration ¢ With a 13% organic growth rate in 2005, we have outperformed the industry: - Global total market for research products growth rate of 5%-6% - NIH funding relatively flat - Pharma pre-clinical expenditures growth rate of ~ 15% - Total c

  14. Slide 14: 2006 Outlook

    2006 Outlook

  15. Slide 15: 2006 Guidance

    2006 Guidance Continue High Revenue and Earnings Growth 2005 Guidance 2006 Guidance Gr Pro Forma Pro Forma ow Revenue $265-270 Million | $295-$305 Million 11%-13% Earnings Per Share $0.92-$0.95 $1.12-$1.16 22% Capital $15 Million $23 Million Expenditures EBITDA $62-$65 32%-34%

  16. Slide 16: Key Initiatives in 2006

    geckos Corporation Key Initiatives in 2006

  17. Slide 17: Research Segment

    Serologicals Research Segment Corporation e Focus on drug discovery and new platforms - Expand leadership positions in current drug discovery target offering and identify new ones (e.g., kinases, GPCRs, HDACs, phosphatases) - Identify promising new platforms/technologies that enable our customers to

  18. Slide 18: Bioprocessing Segment

    Serologicals Bioprocessing Segment Corporation ¢ Focus on delivering superior service - Dedicate continual resources to our EX-CYTE® customers - Streamline customer distribution process ¢ Continue to strengthen our product portfolio - Develop new products: * Animal-free EX-CYTE® * Recombinant human

  19. Slide 19: Acquisition Strategy

    r Acquisition Strategy e Short term: identify additional opportunities in high-growth markets to fill gaps or enter adjacent markets * Long term: identify opportunities to increase scale and portfolio diversification ¢ All transactions must be accretive

  20. Slide 20: Plant Rationalization Decisions

    Plant Rationalization Decisi e We are dedicated to seizing opportunities to reduce expenses and redundancies without compromising our customers’ expectations - Lake Placid Transition ~ Toronto Plans — Lawrence Plans

  21. Slide 21: Lake Placid Transition Update

    Lake Placid Transition Update Plan * Streamlined R&D and administrative functions to Temecula ¢ Transfer all manufacturing operations H1 2006 * Proceed with personnel transfers/replacements as planned Benefits ¢ Scientific expertise concentrated in a single location ¢ Leverages supply chain manageme

  22. Slide 22: Toronto Plans

    onto Plans Plan * Transition all BSA production and other enzyme products to Kankakee in 1H 2006 * Write down plant to net realizable value in Q4 2005 - Book Value: $17 Million - Closure Costs: $2-$3 Million Benefits « Avoids $6-8 Million in cap ex spending required for upgrades e Improves gross mar

  23. Slide 23: EX-CYTE Update

    Serologicals YYTE® Update Corporation *° EX-CYTE® demand continues as expected - 4 FDA approved products - 2 Phase III products - 25+ Early stage projects « Kankakee capacity increased by 50% in 2005 - Process improvements streamline and de-bottleneck production - Margins improve by 400-500 basis po

  24. Slide 24: Lawrence Plans

    wrence Plans Plan Benefits * Write down plant to net * Meets expanding EX- realizable value in Q4 2005 CYTE® customer (NBV: $33 Million) demand e Prepare facility for sale ¢ Continues to improve - Cost of closure: $3 - $4 gross margins Million ¢ Improves customer ¢ Continue to identify margin servic

  25. Slide 25: Investing for the Future

    Serologicals Investing for the Future Cope” E-Commerce & Com) Other IS Projects Temecula Expansion Kankakee Expansion © s7.0" > & Conversion Projects Dundee Cem) Capacity Additions Maintenance © $5.0M ») Total —————_________+ C s23.0m >

  26. Slide 26: Other Financial Metrics for 2006

    Serologicals* Other Financial Metrics for 2006 Corporation jancial Metrics * Free cash flow - $40 Million up 25% * DSO — Improve to 55 days outstanding from 60 days + Return on net assets - 15% + * Stock option expense - $0.04-$0.06 or $3.3 Million pre-tax

  27. Slide 27: 2005 Quarterly Results

    2005 Quarterly Results 2005 Results Revenue Pro Forma EPS aul Ql 21% 14% Q2 24% 20% —_ Q3 25% 29% =] a4 30% 37% Uses midpoint of 2005 guidance

  28. Slide 28: Searchable text section of graphics shown above

    Searchable text section of graphics shown above 2 006 Guidance [LOGO] [GRAPHIC] building value, enhancing lives January 2006 [ L OGO] Safe Harbor This presentation may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, wit

Serologicals — Investor Presentation (January 2006) on 6ix